In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Galena partners cancer immunotherapeutic NeuVax with Teva in Israel

Executive Summary

Oncology company Galena Biopharma Inc. has licensed Teva Pharmaceutical Industries Ltd.’s Israeli division ABIC Marketing Ltd. exclusive rights to market its Phase III breast cancer immunotherapeutic NeuVax (nelipepimut-S) in Israel. Teva also received a right of first refusal on all other future indications.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies